Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.

Neurogastroenterology and motility - 1 Jan 2024

Patel Milan, Partovi Omeed, Karrento Katja, Garacchi Zhuping, Balasubramanian Gokulakrishnan, Venkatesan Thangam

Abstract excerpt

BACKGROUND: Amitriptyline (AT) is recommended as first-line prophylactic therapy in patients with cyclic vomiting syndrome (CVS). However, significant side effects limit its use and dosing is based on trial and error. Though the Clinical Pharmacogenetic Implementation Consortium (CPIC) Guidelines recommend dosing for AT based on CY2D6 and CYP2C19 genotype profile, this is not followed in clinical practice....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenomic Testing

Share to Pilot Projects

Share to Vomiting

Share to Young Adult

Source

Identifiers

PMID: 37953495
DOI: 10.1111/nmo.14705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.PMID 37953495Read ↗

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.Semantic proximity Read ↗

Doxepin Drug-Drug and Drug-Gene Interactions: Clinical Implications and Mechanistic InsightsSemantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.Semantic proximity Read ↗

Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.Semantic proximity Read ↗

Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetineSemantic proximity Read ↗

Evaluating the Clinical Impact of CYP2C19 and CYP2D6 on Amitriptyline Outcomes in a Real-World Chronic Pain CohortSemantic proximity Read ↗

CYP2C19 drug-drug and drug-gene interactions in ED patients.Semantic proximity Read ↗

CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders.Semantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?Semantic proximity Read ↗

Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.